You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
創美藥業(02289.HK)中期純利2596.1萬元 同比減少15.91%
格隆匯 08-20 21:25

格隆匯8月20日丨創美藥業(02289.HK)公佈,截至2021年6月30日止6個月,公司營業收入19.93億元人民幣,同比增長7.11%;歸屬於母公司股東的淨利潤2596.1萬元,同比減少15.91%;每股收益0.2404元。

公司的主要業務是於中國分銷藥品,而絕大部分營業收入來自藥品分銷。公司從醫藥生産商及分銷供應商採購藥品,銷售予分銷商,零售藥店,及醫院、診所、衞生站及其他類客户。公司遵循制定的經營目標,繼續深耕廣東及輻射周邊市場,積極拓展零售終端網絡。

截至2021年6月30日,公司的分銷網絡覆蓋10,639名客户,其中619名為分銷商,6,634名為零售藥店,3,386名為醫院、診所、衞生站及其他。較上年度,客户數量增加2,265名,其中分銷商增加55名,零售藥店增加1,032名,醫院、診所、衞生站及其他增加1,178名。為滿足客户不同需求及增強客户黏合度,公司與國內外知名廠商加強合作,提高一級經銷産品的品種和規模;持續優化産品結構,引進適銷、毛利率高的優質産品,豐富産品種類。

截至2021年6月30日,公司共有供應商1,007名,其中醫藥生産商614家及分銷供應商393家。較上年度同期增加35名。截至2021年6月30日止,公司分銷11,841種産品,較上年度增加2,220種。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account